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Abstract
Background: The aim was to investigate HRQoL and psychosocial function among patients with
carcinoid tumours, longitudinally and prospectively, and to compare HRQoL among patients with
carcinoid tumours to that of the Swedish general population. The aim was also to investigate the
prevalence of distress during the first year after diagnosis.
Methods: At four assessments during the first year after diagnosis, HRQoL was measured by the
EORTC QLQ-C30 3.0, anxiety and depression by the HADS, and prevalence, and worst aspects of
distress by an interview guide. ANOVA was performed in order to study changes over time with
regard to HRQoL, anxiety and depression. Comparisons regarding HRQoL between patients and
the Swedish population were made by the use of one-sample t-tests and changes over time
regarding the prevalence of distress was investigated by means of Cochran's Q.
Results: High levels of physical-, emotional-, cognitive-, and social function and somewhat lower
levels of role function and global quality of life were reported at all assessments. Role- and
emotional function increased over time. Patients reported lower role function and global quality of
life and more problems with fatigue and diarrhoea than the Swedish general population, at all
assessments. Fatigue, limitations to work and pursue daily activities, and worry that the illness will
get worse were among the most prevalent aspects at all assessments. At all assessments the
majority reported worrying about the family's situation, the ability to care for the family, and
worrying before the check-up.
Conclusion: It is concluded that HRQoL and psychosocial function among patients with carcinoid
tumours remains stable during the first year, that the patients report a lower HRQoL than the
Swedish general population, and that a majority of the patients report a number of aspects of
emotional distress. In the clinical care, it should be considered that the majority of patients report
not only fatigue and diarrhoea but also worries about their prognosis, their families, tests, and
examinations. Efforts to reduce these worries should be made.
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Background
Carcinoid tumours are slow-growing malignancies
belonging to the family of neuroendocrine tumours, the
incidence is 2.5 in 100 000 [1]. The most common type is
midgut carcinoid tumours with a 5-year survival rate of
61% [1]. Neuroendocrine tumours can be divided into
functioning and non functioning tumours. Functioning
tumours cause symptoms related to an overproduction of
hormones while non-functioning tumours produce pep-
tides that do not cause symptoms [1]. Symptoms caused
by functioning tumours are flush, diarrhoea, bronchial
constriction, and right heart failure caused by overproduc-
tion of varying hormones. Abdominal pain due to the
tumour itself, lymph node or liver metastases may occur
[1]. Surgery is the only treatment that can cure the
patients. Some, but not all benefit from chemotherapy.
The management usually includes treatment with biolog-
ical agents such as somatostatin analogues and interferon-
α [1]. Both agents control the disease but do not provide
a cure. The aims of treatment are to reduce hormone lev-
els, control hormonal symptoms, prevent further tumour
growth, and possibly also tumour reduction [1].
Common adverse effects of somatostatin analogues are
nausea, abdominal cramps, loose stools, mild steathorrea,
and flatulence. These symptoms usually decrease within a
few weeks. Flu-like symptoms are very common, usually
short lasting, consequences of interferon treatment.
Chronic fatigue and mild depression may develop in
approximately 50% of the patients treated with interferon
[2]. The treatment should be carefully monitored by a
complete history and physical examination approxi-
mately every 3 months [2]. Biochemical parameters
(tumour markers) are tested every 3 to 6 months and the
patients should be examined using conventional imaging
studies (CT, MRI, ultrasonography, octreoscan) every 6
months [2,3].
It has been reported that patients with carcinoid tumours
enjoy a good health related quality of life (HRQoL) and
low levels of anxiety and depression, in early as well as
later stages of the disease [4-6]. However, the findings of
a longitudinal, prospective study in which 24 patients
with carcinoid tumours were included indicate that they,
during the first year of treatment with somatostatin ana-
logues and/or interferon-α, report a lower emotional- and
role function, lower global quality of life and more prob-
lems with fatigue, nausea/vomiting, appetite loss, and
diarrhoea compared to the Swedish general population
[6].
Since carcinoid tumours may be presented with problems
typical for the disease it was questioned whether the
EORTC QLQ-C30 and Hospital Anxiety and Depression
Scale, previously used to measure patients' with carcinoid
tumours psychosocial function [4-6], included all prob-
lems that may be of relevance for the patients. Therefore,
an interview study with patients with carcinoid tumours,
and staff caring for them was undertaken [7]. The findings
indicate that the patients report a number of physical,
social, and emotional aspects of distress [7]. Pain and
flush are examples of aspects of physical distress [7]
whereas limited possibilities to work/pursue daily activi-
ties are examples of aspects of social distress and worry
that the disease will get worse an example of emotional
distress [7]. Several of the identified aspects of distress are
not included in the EORTC QLQ-C30 [8] or the Hospital
Anxiety and Depression Scale [9]. In the studies [4-7]
referred to above, the time the patients had been living
with their disease varied from 1 to 96 months which lim-
its the possibilities to make conclusions regarding the
patients' HRQoL, and levels of anxiety and depression, at
certain time-points during the course of the disease. This
circumstance, together with the fact that the prevalence of
disease-related aspects of distress among patients with car-
cinoid tumours has not been investigated indicates that
there is room for more knowledge about how patients
with carcinoid tumours experience their life situation.
The present study sets out to add to knowledge about
HRQoL and psychosocial function among patients with
carcinoid tumours by following a group of individuals
over time, starting shortly after diagnosis. The following
research questions were posed: 1. Do patient ratings of
HRQoL, anxiety, and depression change over time from
diagnosis?; 2. How do patients rate their HRQoL com-
pared to the Swedish general population shortly after each
of the first four admissions to hospital?; 3. What is the
prevalence of physical, social, and emotional aspects of
distress shortly after each of the first four admissions to
hospital?; 4. Which physical, social, and emotional
aspects of distress are reported as the worst shortly after
each of the first four admissions to hospital? and 5. Does
the prevalence of physical, social, and emotional aspects
of distress change over time from diagnosis?
Methods
Design
This study is based on a longitudinal, prospective design
with four assessments (T1–T4). Each of these occurred
shortly after each of the patients' first four admissions to
the Department of Endocrine Oncology (DepEO), Upp-
sala University Hospital, Uppsala, Sweden.
Sample and setting
To be eligible patients should be referred to the DepEO for
the first time, age ≥18 years, have a good command of the
Swedish language, and not be cognitively impaired. Dur-
ing the inclusion period (April 2001–August 2003) 103
patients with a suspected diagnosis of carcinoid wereHealth and Quality of Life Outcomes 2007, 5:18 http://www.hqlo.com/content/5/1/18
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referred to the DepEO. Five of these were not asked about
participation due to administrative reasons, of the
remaining patients 76 accepted participation. At T1, 17
patients were excluded for the following reasons: 7 were
not diagnosed with carcinoid, 6 would not be further
referred to the DepEO, and 4 were too ill to participate.
Thus, 59 patients were included in the study at T1, 36 of
these participated at all assessments (T1–T4). Data from
these patients are reported in this study and their medical
and demographic characteristics are presented in Table 1.
For a presentation of reasons for attrition at T2–T4, see
Table 2. The patients in the study were referred to the
DepEO from several hospitals in Sweden, for a diagnosis
or a verification of a suspected diagnosis of carcinoid
tumours. The patients participating in the study were all
in-patients, the mean duration of each hospital admission
was 6 days (SD = 2) at the first, 4 days (SD = 1) at the sec-
ond, 3 days (SD = 1) at the third, and 3 days (SD = 0.7) at
the fourth admission. During these admissions, patients'
biochemical parameters (tumour markers) could be
tested, and patients could be subjected to conventional
imaging studies such as CT, MRI, ultrasonography, octre-
oscan [2,3] and in some cases patients received treatment
(see Table 1). The mean time between the first and the sec-
ond admission was 3 months (SD = 1.3), 4 months (SD =
1.4) between the second and the third, and 5 months (SD
= 1.7) between the third and the fourth admission.
Procedure
Ethical approval was obtained from the local ethics com-
mittee at the faculty of Medicine at Uppsala University.
The first author (CF) provided potential participants with
oral and written information about the aim and proce-
dure of the study at their first admission to the DepEO.
They were informed that participation was voluntary, that
confidentiality was guaranteed, and that neither participa-
tion, non-participation or withdrawal would affect their
treatment and care. Shortly thereafter CF asked patients
about consent. Patients who accepted participation and
were eligible at T1, T2, T3, and T4 received the instru-
ments (see Instruments) at the preceding admission to the
DepEO. Patients were asked to complete these at home,
after their hospital-stay, and a time when the patient
should be asked to provide his/her responses via tele-
phone, was agreed upon with CF. Data was collected from
one week up to one month after each admission. Medical
and demographic data were collected from the medical
journals by CF.
Instruments
HRQoL
HRQoL was measured with the EORTC QLQ-C30 3.0 [8]
which includes 30 questions incorporated in five func-
tional scales: physical (PF), role (RF), cognitive (CF),
emotional (EF), and social (SF), three symptom scales:
fatigue (FA), pain (PA), and nausea and vomiting (NV),
and a global health and quality of life scale (QL). Also
included are single items assessing: dyspnoea (DY), appe-
tite loss (AP), sleep disturbance (SL), constipation (CO),
diarrhoea (DI), and perceived financial impact (FI) of the
disease and treatment. Responses were provided on Likert
scales, coded 1–4 with the response alternatives not at all,
a little, quite a bit, and very much. Responses for global
health and quality of life were provided on scales with the
end-points 1 (very poor) and 7 (excellent). The scores
were transformed in accordance with the EORTC guide-
lines to 0–100 scores [10]. A higher score on functional
scales represents a higher level of function, while a higher
score on symptom scales represents a higher level of
symptoms. Good reliability and validity has been shown
for the instrument [8]. In this study, Cronbach's alpha val-
ues for the subscales were >.70 at T1–T4, with the excep-
tion of RF (.60 at T2), CF (.35 at T2, .46 at T3, and .67 at
T4), NV (.43 at T1, .65 at T3, and impossible to compute
alpha at T4). Patients were asked to answer the questions
according to the last week.
Anxiety and depression
Anxiety and depression was measured with the Hospital
Anxiety and Depression Scale (HADS) [9]. The instrument
consists of two subscales (7 items in each subscale), one
measuring anxiety (A) and one depression (D). Responses
are provided on verbal scales, coded 0–3. Subscale scores
range from 0 to 21. The HADS has proved to be a useful
clinical indicator of anxiety and depression [11-13]
among patients with somatic illnesses. Cronbach's alpha
values at T1–T4 were high for the anxiety (.80–.90) and
the depression subscale (.82–.92.). Patients were asked to
answer the questions according to the last week.
Aspects of distress
In a previous study [7] patients and nurses were posed
semi structured interview questions about distress related
to the disease and treatment. The data was analysed using
content analysis (7), and 24 aspects of distress were iden-
tified. These aspects were related to 3 dimensions; physi-
cal (10 aspects), social (5), and emotional (10) aspects of
distress [7] (see Table 5 for a presentation of the dimen-
sions and aspects of distress). By using these aspects of dis-
tress as a starting point, an instrument was constructed for
the present study, aiming at measuring the prevalence,
and worst aspects of distress. The instrument consists of 3
dimensions, a physical (10 aspects), social restrictions (5
aspects), and emotional (9 aspects) dimension (in the
present study the aspect worry before illness was omitted
from the emotional dimension). For each aspect patients
were asked to rate the level of distress, and provide their
responses on a Likert scale from 0 (no distress) to 5 (very
much distress). Thereafter the patients were asked, by a
separate question, to identify which of the aspect that hadHealth and Quality of Life Outcomes 2007, 5:18 http://www.hqlo.com/content/5/1/18
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been the worst, within each dimension. For the dimen-
sion social distress, the patients were asked to state which
of the 10 aspects of physical distress they perceived had
caused social distress. Patients were encouraged to iden-
tify only one aspect as worst, within each dimension, but
when patients chose to report more than one aspect as
being the worst, all reported aspects were included in the
presentation of the results. Patients were asked to answer
the questions according to the last four weeks.
Background data
Patients were asked to report age, gender, civil status and
occupational status. Data on medical variables such as
treatment, metastasis, surgery, and biochemical parame-
ters were gathered through the patients' medical records.
Data analysis
All statistical analyses were conducted using the Statistical
Package for the Social Sciences (SPSS) version 14.0 (SPSS
Inc, Chicago, IL). Research question 1 was answered by
repeated measures ANOVA whereas research question 2
was answered by one-sample t-test. As suggested by others
[14] a difference of more than 10 points between two val-
ues for the same variable in EORTC QLQ-C30 was consid-
ered as indicating a difference of clinical interest. For the
comparison between patient scores on the EORTC QLQ-
C30 and corresponding Swedish population norms [15],
corrections for age and gender were made. When calculat-
ing prevalence of aspects of distress it was assumed that if
a patient answered "no distress" in response to a question
about an aspect, the same aspect was not prevalent for the
same individual. Remaining response alternatives were
assumed to indicate that the aspect, at least to some
extent, was experienced as distressing and thus prevalent.
Research question 5 was answered by Cochran's Q.
Missing values for the EORTC QLQ C-30 were replaced
according to the manual for the EORTC QLQ C-30 [10].
After replacing missing values the internal dropout for
EORTC QLQ C-30 was <2% at T2. Missing values for the
HADS were replaced by the mean values of the patient's
answers to the remaining items of the respective subscale,
provided that at least four of the items in the subscale had
been answered. Missing values for the interview guide
Table 2: Reasons for attrition at T2–T4
Reason for attrition T2 T3 T4
Withdrawal of consent 531
Patients would not be further referred to the Department of Endocrine Oncology 4 2 2
Death -13
Too ill to participate 1-1
Total 10 6 7
Table 1: Background data at T1 for patients (N = 36). All figures represent number of patients unless stated
T1 T2 T3 T4
Male 19 (53%)
Female 17 (47%)
Mean age (SD) 60 (10%)
Married/cohabiting 25 (70%)
Working 7 (19%)
On sick leave 14 (39%)
Old age pensioner 15 (42%)
Metastatic 25(70%) 28 (78%) 28 (78%) 28 (78%)
Levels of Chromogranin A, nmol/liter (ref < 4) 37 42 53 76
Levels of U-5HIAA, μmol/h (ref < 2.1) 13 12 23 14
Mean time since surgery, months1,2 (SD) 3.1 (2.5)
Interferon 5 (14%) 8 (22%) 6 (27%) 4 (11%)
Octreotid 5 (14%) 6 (27%) 6 (27%) 6 (27%)
Interferon and Octreotid 6 (27%) 10 (28%) 12 (33%) 9 (25%)
Other (Chemotherapy) 4 (11%) 5 (14%) 6 (27%) 3 (<1%)
Octreotid and chemotherapy - - - 1 (<1%)
No treatment 16 (44%) 7 (19%) 6 (27%) 13 (36%)
1 14 patients had surgery prior to the first admission to the Department of Endocrine Oncology.
2 3 patients had surgery between the first and second admission to the Department of Endocrine Oncology.Health and Quality of Life Outcomes 2007, 5:18 http://www.hqlo.com/content/5/1/18
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were not replaced. The internal dropout for aspects of
physical distress was 0.5–3% at T1–T4, social distress 0–
3% at T1–T4, and emotional distress 0–4% at T1–T4.
A significance level of p < .01 was chosen for all statistical
analyses.
Results
See Table 1 for a presentation of demographic and medi-
cal background data for the patients participating in the
study.
HRQoL, anxiety, and depression
Mean values and standard deviations for HRQoL, anxiety,
and depression at T1–T4 are presented in Table 3. The
mean values for role function and global quality of life
were somewhat lower than for the remaining scales at all
assessments. At all assessments the highest level of prob-
lems were reported for fatigue followed by pain, dysp-
noea, and diarrhoea. Low mean values were reported for
anxiety and depression at all assessments.
Patients reported lower emotional function at T3 com-
pared to T4 [F(3, 102) = 3.50; p < .01].
The mean value for role function increased more than 10
points, i.e. of clinical interest, from T1 to T2, T3, and to
T4.
See Table 4 for a presentation of the observed scores and
population norms for HRQoL at T1–T4. The difference
between scores was larger than expected by chance for role
function at T1–T3 (t = 3.26–4.99, df = 34–35, p < .01,
.001), social function at T1 (t = 3.17, df = 35, p < .01), and
global quality of life at T1–T4 (t = 3.74–5.75, df = 34–35,
p < .01, .001). The observed score was more than 10
points below the population norms for role- and social
function, and global quality of life at all assessments and
at all assessments, the observed score was more than 10
points above the population norms for fatigue and diar-
rhoea. All these differences were larger than expected by
chance (t = 3.16–5.71, df = 34–35, p < .01, .001). At T2 the
observed score was more than 10 points higher than the
population norms for appetite loss (t = 2.93, df = 34, p <
.01), and at T3 and T4 the observed score was more than
10 points higher than the population norms for dysp-
noea.
Aspects of distress
See Table 5 for a presentation of prevalence and worst
aspects of distress at T1–T4. Fatigue was the most preva-
lent, and flush, pain-stomach, dyspnoea, dry skin/mucous
membranes, diarrhoea, and appetite loss were among the
most prevalent aspects of physical distress at all assess-
ments. At all assessments fatigue and diarrhoea were
reported as the worst aspects of physical distress by most
patients. A difference over time with regard to the preva-
lence of flush (Q (3) 13.2, p < .005), with a lower preva-
lence at T4 than at T1–T3, and dry skin/mucous
membranes (Q (3) 12.7, p < .005), with a higher preva-
lence at T4 than at T1 was demonstrated.
Limited possibilities to work/pursue daily activities and to
perform physical activities were the most prevalent
aspects of social distress at all assessments. At T1–T3 lim-
ited possibilities to work/pursue daily activities was
reported as the worst aspect of social distress by most
patients. At T4 an equal number of patients reported this
aspect and limited possibilities to perform physical activ-
ities and to dine out/go to theatre as the worst aspect of
social distress. Fatigue followed by diarrhoea and dysp-
noea were reported most frequently as the aspects causing
social distress at all assessments.
Worry that the illness will get worse was the most preva-
lent, and depression, irritation, worry that the family can-
not cope with the illness, and worry before check-up were
among the most prevalent emotional aspects of distress at
the respective assessment. At all assessments worry that
the illness will get worse was reported as the worst aspect
of emotional distress by the majority of the patients. A dif-
ference over time with regard to the prevalence of bother
by changed appearance (Q (3) 12.0, p < .01) with a higher
prevalence at later assessments than at T1 was demon-
strated.
When looking at the prevalence of all aspects of distress
together, worry that the illness will get worse was the most
prevalent aspect followed by depression, worry that the
family cannot cope with the illness, irritation, and worry
before check-up at T1. At T2 the corresponding aspects
were worry that the illness will get worse, fatigue, worry
that the family can not cope with the illness, depression,
and irritation, at T3 fatigue, worry that the illness will get
worse, depression, irritation, limited possibility to per-
form physical activities, and worry that the family can not
cope with the illness, and at T4 worry that the illness will
get worse, fatigue, limited possibility to perform physical
activities, irritation, worry before check-up, and limited
possibility to work/pursue daily activities. Most of these
aspects are of an emotional nature.
When taking together all aspects of distress that patients
reported as being the worst, worry that the illness will get
worse, fatigue, and limited possibility to work/pursue
daily activities were the aspects considered the overall
worst by most patients at T1–T3, when looking at the
three dimensions together. At T4 the corresponding
aspects were: fatigue, worry that the illness will get worse,
and diarrhoea.Health and Quality of Life Outcomes 2007, 5:18 http://www.hqlo.com/content/5/1/18
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Table 3: Mean values (M) and standard deviations (SD) for the EORTC QLQ-C30 scales and single items and the HADS subscales at 
(T1–T4) (n = 36)
Scales/single items T1 T2 T3 T4
M, SD M, SD M, SD M, SD
PFa 80 (22) 80 (20) 81 (22) 79 (22)
RFa 53 (39) 64 (31) 69 (28) 69 (35)
EFa 77 (20) 75 (23) 75 (21) 82 (19)
CFa 85 (21) 85 (17) 83 (18) 84 (18)
SFa 77 (26) 80 (28) 80 (26) 79 (27)
QLa 58 (19) 61 (23) 58 (24) 58 (25)
FAb 35 (26) 38 (27) 35 (24) 34 (24)
NVb 3 (8) 10 (20) 6 (12) 7 (12)
PAb 20 (28) 23 (31) 27 (33) 21 (27)
DYb 27 (31) 22 (24) 30 (36) 29 (34)
SLb 18 (24) 11 (18) 13 (18) 18 (26)
APb 10 (19) 18 (28) 8 (17) 13 (24)
COb 9 (22) 13 (22) 10 (21) 9 (23)
DIb 25 (35) 21 (29) 23 (31) 30 (27)
FIb 14 (23) 15 (26) 12 (23) 14 (26)
Ac 5.1 (4.1) 5.1 (4.7) 4.4 (3.9) 4.1 (3.4)
Dc 4.1 (3.7) 4.6 (4.6) 5.0 (4.0) 4.5 (3.6)
PF = Physical function, RF = Role function, CF = Cognitive function,
EF = Emotional function, SF = Social function, QL = Global quality of life,
FA = Fatigue, NV = Nausea/vomiting, P = Pain, DY = Dyspnoea,
SL = Sleep disturbances, AP = Appetite loss, CO = Constipation,
DI = Diarrhoea, FI = Perceived financial impact, A = Anxiety, D = Depression
a Scores range from 0 to 100, a higher score represents a higher level of function.
b Scores range from 0 to 100, a higher score represents a higher level of symptoms.
c Scores range from 0–21, a higher score represents a higher level of problems.
Table 4: Mean (M) for observed scores (O) and population norms (P) and differences (D) between the observed scores and population 
norms for the EORTC QLQ C-30 scales and single items at T1–T4
T1 T2 T3 T4
OPDOPDOPDOPD
MMDMMDMMDMMD
PFa 80 87 -7 80 87 -7 81 87 -6 79 87 -8
RFa 53 85 -32** 64 85 -21** 69 85 -16* 69 85 -16
EFa 77 83 -6 75 83 -8 75 83 -8 82 83 -1
CFa 85 88 -3 85 88 -3 83 88 -5 84 88 -4
SFa 77 91 -14* 80 91 -11 80 91 -11 79 91 -12
QLa 58 76 -18** 61 76 -15** 58 76 -18** 58 76 -18**
FAb 3 52 1 1 4 * 3 82 1 1 7 * * 3 52 1 1 4 * * 3 42 1 1 3 *
NVb 330 1 0 37633734
Pb 2 0 2 002 3 2 032 7 2 072 1 2 01
DYb 27 17 10 22 17 5 30 17 13 29 17 12
SLb 18 19 -1 11 19 -8 13 19 -6 18 19 -1
APb 10 4 6 18 4 14* 8 4 4 13 4 9
COb 9 6 31 36 71 06 4 9 6 3
DIb 25 5 20* 21 5 16* 23 5 18* 30 5 25**
FIb 1 4 86 1 5 87 1 2 84 1 4 86
PF = Physical function, RF = Role function, CF = Cognitive function, EF = Emotional function, SF = Social function, QL = Global quality of life, FA = 
Fatigue, NV = Nausea/vomiting, P = Pain, DY = Dyspnoea, SL = Sleep disturbances, AP = Appetite loss, CO = Constipation, DI = Diarrhoea, FI = 
Perceived financial impact, A = Anxiety, D = Depression
a Scores range from 0 to 100, a higher score represents a higher level of function.
b Scores range from 0 to 100, a higher score represents a higher level of symptoms.
* p < .01, ** p < .001Health and Quality of Life Outcomes 2007, 5:18 http://www.hqlo.com/content/5/1/18
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Discussion
At all assessments patients reported high levels of physi-
cal-, emotional-, cognitive-, and social function however
somewhat lower levels of role function and global quality
of life. Most problems were reported with fatigue, dysp-
noea, diarrhoea, and pain. The results support previous
results and taking the present results into consideration,
together with previous results, [5,6,16] it may be con-
cluded that patients with carcinoid tumours enjoy good
HRQoL from the early stages of the disease as well as later
on. Patients' role- and emotional function increased over
time. Apart from these changes patients' HRQoL and psy-
chosocial function did not change during the first year
after diagnosis. On one hand it could be expected that
once patients receive their diagnosis and treatment aiming
at reducing the hormone-related symptoms is initiated,
patients' HRQoL and psychosocial function should
increase. On the other hand it could be expected that
patients' HRQoL and psychosocial function, as a conse-
quence of the illness itself and disruption of the previous
normal life, should decrease over time. However, the
results do not support any of these expectations. The lack
of significant and/or clinically relevant changes could also
be explained by methodological circumstances such as a
small sample and inappropriate instruments and/or by, if
it is assumed that HRQoL and psychosocial function
ought to deteriorate over time, an adaptation to a difficult
life situation.
When comparing the patients' HRQoL to the Swedish
population norms, it is revealed that the patients' HRQoL
is significantly lower in a statistical sense than that
reported by the Swedish population for fatigue, diarrhoea,
and overall quality of life at all assessments and for role
function at the first three assessments. The findings sup-
port previous results [6]. In this study clinical significance,
in most cases, coincides with statistical significance which
highlights that identified differences between patients
with carcinoid tumours and the Swedish population are
of clinical relevance.
Some of the patients in the present study were treated with
interferon and it is known that interferon may cause
fatigue and mild depression [2]. In this study we found it
Table 5: Prevalence and worst aspects of physical, social, and emotional distress at T1–T4 (n = 36)
T1 T2 T3 T4
Prevalence Worst1 Prevalence Worst1 Prevalence Worst1 Prevalence Worst1
Physical distress
Fatigue 25 (69%) 11 31 (86%) 15 32 (89%) 12 30 (83%) 17
Diarrhoea 18 (50%) 10 20 (56%) 10 22 (61%) 11 25 (69%) 13
Dry skin/mucous membranes 14 (39%) 2 22 (61%) 5 22 (61%) 3 25 (69%) 6
Pain-stomach 18 (50%) 4 20 (56%) 3 20 (56%) 8 23 (64%) 4
Dyspnoea 18 (50%) 3 21 (58%) 5 20 (56%) 8 21 (58%) 10
Flush 19 (53%) 8 21 (58%) 1 21 (58%) 5 11 (30%) 1
Appetite loss 14 (39%) 1 17 (47%) 5 21 (58%) 4 15 (42%) 4
Pain-muscles 15 (42%) 1 17 (47%) 6 15 (42%) 5 18 (50%) 6
Nausea 14 (39%) 1 15 (42%) 3 19 (53%) 5 17 (47%) 6
Insomnia 13 (36%) 4 15 (42%) 3 17 (47%) 1 18 (50%) 5
Social distress 13
Work/pursue daily activities 23 (64%) 15 24 (67%) 15 24 (67%) 13 26 (72%) 6
Perform physical activities 23 (64%) 7 23 (64%) 3 25 (69%) 10 27 (75%) 6
To travel 20 (56%) 2 17 (47%) 5 23 (64%) 8 21 (58%) 2
Dine out/go to theatre etc 17 (47%) - 18 (50%) 3 19 (53%) 6 19 (53%) 6
Associate with friends 17 (47%) 3 17 (47%) 3 20 (56%) 6 18 (50%)
Emotional distress
Worry that the illness will get worse 33 (92%) 20 32 (89%) 10 30 (83%) 16 31 (86%) 16
Depression 32 (89%) 1 27 (75%) 5 29 (80%) 9 26 (72%) 10
Irritation 27 (75%) 5 26 (72%) 5 29 (80%) 6 27 (75%) 6
Worry that the family can not cope with the illness 29 (80%) 6 29 (80%) 4 25 (69%) 5 23 (64%) 7
Worry before check-up 27 (75%) 4 25 (69%) 3 24 (67%) 7 26 (72%) 7
Worry that the illness will interfere with ability to 
care for the family
25 (69%) 5 21 (58%) 3 24 (67%) 5 22 (61%) 1
Troublesome tests/examinations 25 (69%) 4 17 (47%) 4 20 (56%) 1 24 (67%) 2
Bother by changed appearance 7 (19%) - 14 (39%) 1 18 (50%) 2 17 (47%) 3
Bother by changed sexual activity 13 (36%) - 14 (39%) - 16 (44%) 1 19 (53%) 2
1 Some patients reported more than one aspect of distress as being worst.Health and Quality of Life Outcomes 2007, 5:18 http://www.hqlo.com/content/5/1/18
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difficult to analyze potential differences in HRQoL and
psychosocial function between patients treated with inter-
feron versus patients treated with chemotherapy, octre-
otide or no treatment at all, due to small sub-groups.
The sample may be considered small from a statistical
point of view. However, when considering the size of the
sample it should be remembered that carcinoid tumours
are very rare. The patients were consecutively included
during approximately two and a half years at the Depart-
ment of Endocrine Oncology, Uppsala University Hospi-
tal, at the time of the study the main centre in Sweden
specialized in treating endocrine tumours. In addition,
the sample is unique since it is homogenous with regard
to time since diagnosis and the timing of the assessments.
The present study is to the best of our knowledge one of
only a few studies in which patients with carcinoid
tumours have been asked to rate their HRQoL, anxiety,
and depression repeatedly after diagnosis. When consid-
ering the generalizability of the findings it is important to
consider the number of non-participants and drop-outs
and whether these persons differ from the participants. It
is possible that if health should deteriorate, patients may
choose to withdraw. However, analyses investigating
whether the participating patients' HRQoL and psychoso-
cial function differed from that of the dropouts at T1 did
not show any differences.
This study investigated the prevalence of some inductively
derived aspects of physical, social, and emotional distress
previously found to be of relevance for patients with car-
cinoid tumours [7]. By presenting the prevalence of these
aspects and which of these that were considered to be the
worst, the psychosocial function of patients with carci-
noid tumours was further illuminated. The findings dem-
onstrate that fatigue was the most prevalent and diarrhoea
among the four most prevalent aspects of physical distress
at all assessments as well as considered the worst aspects
of physical distress by most patients at all assessments.
The findings with regard to physical aspects of distress cor-
respond with the EORTC QLQ C-30 data as these demon-
strate at least high levels of problems with fatigue and
diarrhoea at all assessments and a higher level of problem
with these concerns than that for the Swedish general
population at all assessments.
Limitations with regard to pursuing work, and daily- and
physical activities were the most prevalent aspects of
social distress at all assessments and limitations with
regard to work and daily activities was considered the
worst of these aspects by most patients at all assessments.
Fatigue and diarrhoea were, at all assessments, reported as
the most frequent reasons for social restrictions, which
underscores the importance of realizing the important
consequences of these problems.
Worry that the illness will get worse was the most preva-
lent as well as considered the worst aspect of emotional
distress by most respondents at all assessments. The
results show that the majority of the patients, at all assess-
ments, worried, at least to some extent, about how their
families would cope with the disease and about whether
they would be able to care for their families in spite of the
disease. A substantial number of the patients also reported
worrying before troublesome tests and examinations and
about what the test results would show. None of these
aspects of emotional distress are included in the EORTC
QLQ-C30, at the time of the study, the HRQoL instrument
that previously had been used when investigating HRQoL
among patients with endocrine gastrointestinal tumours
[5,6,16]. A majority of the patients worry about a number
of disease- and treatment related concerns at all assess-
ments as well as report feeling depressed and irritated at
all assessments.
Although the reported prevalence of physical, social, and
emotional distress does not provide knowledge about the
significance of the aspects of distress, the results illustrates
that there are several aspects of emotional distress likely to
be of concern for the patients. While the EORTC QLQ C-
30, and especially the new carcinoid module [17] well
covers the physical aspects of the carcinoid disease, and
the HADS cover the levels of anxiety and depression,
many concerns of a more emotional matter may be unrec-
ognized by doctors who care for these patients. Thus, in
this study, sensitivity has been prioritized over specificity,
as it is our belief that it is important to be aware of what
problems patients with carcinoid tumours may be pre-
sented with, and which of these problems patients report
as being the worst. Further, these findings with regard to
aspects of distress give another impression concerning the
psychosocial function of patients' with carcinoid tumours
than those from the EORTC QLQ-C30 which indicate that
the patients enjoy good psychosocial function at all
assessments. However, on the basis of the findings from
this study it cannot be concluded which picture that best
illustrates the life situation of these patients – they do
however illustrate that patients with carcinoid tumours
may perceive certain disease- and treatment related
aspects not included in the EORTC QLQ-C30 as trouble-
some. The EORTC HRQoL-group has recently developed
a disease-specific module for patients with gastrointesti-
nal neuroendocrine tumours [17]. In this module, some
aspects of emotional distress identified in this study, for
instance concerning family life and worry about results
from tests and examinations are included.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2007, 5:18 http://www.hqlo.com/content/5/1/18
Page 9 of 9
(page number not for citation purposes)
Conclusion and implications
It is concluded that HRQoL and psychosocial function
among patients with carcinoid tumours remains stable
during the first year after diagnosis, that the patients
report a lower HRQoL than the Swedish general popula-
tion, and that a majority of the patients report a number
of aspects of emotional distress. In the clinical care of
these patients, in addition to paying attention to the phys-
ical problems such as diarrhoea and fatigue it should also
be considered that the majority of the patients also worry
about their prognosis, their families, tests, and examina-
tions. Efforts to reduce these worries should be made.
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